Literature DB >> 22539486

Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.

Lisa K Stamp1, Murray L Barclay, John L O'Donnell, Mei Zhang, Jill Drake, Christopher Frampton, Peter T Chapman.   

Abstract

OBJECTIVE: To determine the effects of furosemide on serum urate (SU), plasma oxypurinol and urinary urate.
METHODS: Twenty-three cases with gout receiving furosemide and allopurinol were recruited. Twenty-three controls with gout receiving allopurinol but no diuretics were matched on age, gender, estimated glomerular filtration rate and allopurinol dose. SU, plasma oxypurinol and urinary urate were assessed on a single occasion. The effects of a single dose of furosemide 40 mg were examined in a separate group of 10 patients receiving allopurinol but not diuretic.
RESULTS: Cases had significantly higher SU and plasma oxypurinol compared with controls despite receiving similar doses of allopurinol. There was no difference in urinary urate excretion. There was a significant increase in area under the curve (AUC)(0-24) for oxypurinol after administration of furosemide 40 mg.
CONCLUSION: The interaction between allopurinol and furosemide results in increased SU and plasma oxypurinol. The exact mechanisms remain unclear but complex interactions that result in attenuation of the hypouricaemic effects of oxypurinol are likely. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, www.anzctr.org.au, 12609000529246.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22539486     DOI: 10.1093/rheumatology/kes091

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  15 in total

1.  Predicting allopurinol response in patients with gout.

Authors:  Daniel F B Wright; Stephen B Duffull; Tony R Merriman; Nicola Dalbeth; Murray L Barclay; Lisa K Stamp
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

2.  Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.

Authors:  Garry G Graham; Diluk R W Kannangara; Sophie L Stocker; Ian Portek; Kevin D Pile; Praveen L Indraratna; Indira Datta; Kenneth M Williams; Richard O Day
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

Review 3.  Urate-lowering therapy: current options and future prospects for elderly patients with gout.

Authors:  Lisa K Stamp; Peter T Chapman
Journal:  Drugs Aging       Date:  2014-11       Impact factor: 3.923

4.  Individualising the dose of allopurinol in patients with gout.

Authors:  Diluk R W Kannangara; Garry G Graham; Daniel F B Wright; Sophie L Stocker; Ian Portek; Kevin D Pile; Murray L Barclay; Kenneth M Williams; Lisa K Stamp; Richard O Day
Journal:  Br J Clin Pharmacol       Date:  2017-05-28       Impact factor: 4.335

5.  The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.

Authors:  Daniel F B Wright; Lisa K Stamp; Tony R Merriman; Murray L Barclay; Stephen B Duffull; Nicholas H G Holford
Journal:  Eur J Clin Pharmacol       Date:  2013-03-10       Impact factor: 2.953

Review 6.  Allopurinol hypersensitivity: investigating the cause and minimizing the risk.

Authors:  Lisa K Stamp; Richard O Day; James Yun
Journal:  Nat Rev Rheumatol       Date:  2015-09-29       Impact factor: 20.543

7.  The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool.

Authors:  Daniel F B Wright; Nicola Dalbeth; Amanda J Phipps-Green; Tony R Merriman; Murray L Barclay; Jill Drake; Paul Tan; Anne Horne; Lisa K Stamp
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

8.  Influence of genetic variants on renal uric acid handling in response to frusemide: an acute intervention study.

Authors:  Nicola Dalbeth; Jordyn Allan; Gregory D Gamble; Amanda Phipps-Green; Tanya J Flynn; Borislav Mihov; Anne Horne; Robert Doughty; Lisa K Stamp; Tony R Merriman
Journal:  RMD Open       Date:  2017-04-11

Review 9.  Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options.

Authors:  Thomas Bardin; Pascal Richette
Journal:  BMC Med       Date:  2017-07-03       Impact factor: 8.775

Review 10.  Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Markus Bredemeier; Lediane Moreira Lopes; Matheus Augusto Eisenreich; Sheila Hickmann; Guilherme Kopik Bongiorno; Rui d'Avila; André Luis Bittencourt Morsch; Fernando da Silva Stein; Guilherme Gomes Dias Campos
Journal:  BMC Cardiovasc Disord       Date:  2018-02-07       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.